Generic Name: leronlimab
Drug Class: Entry Inhibitors
Approval Status: Experimental
Generic Version Available: No
Experimental Code: PRO 140
PRO 140 is not yet approved by the U.S. Food and Drug Administration, nor has it been been reviewed for inclusion in the DHHS list of recommended HIV treatments.
PRO 140 is an experimental HIV medication. It is an entry inhibitor. PRO 140 is a engineered antibody, known as a monoclonal antibody. These antibodies bind to the CCR5 coreceptor on CD4 cells. Once they do this, HIV cannot successfully bind with the surface of these cells, thus preventing the virus from infecting them.
A Phase III trial of PRO 140 as an adjunct to standard antiretroviral therapy is underway and has shown promising interim results. A Phase II study found that PRO 140 monotherapy maintains viral suppression in people who switch from standard combination antiretroviral therapy.
Adult Dose: A dose for PRO 140 has not yet been determined. The drug is administered via subcutaneous injection once a week.
Pediatric Dose: N/A
Dosing Info: N/A
Information regarding the safety and possible side effects of PRO 140 in HIV-positive people has not yet ben reported. Studies to determine the potential side effects of PRO 140 are planned or ongoing.
No studies have yet reported whether PRO 140 may interact with other drugs. Trials to determine potential drug interactions are planned or ongoing. PRO 140 might interact with other medications, including those used to treat HIV. It is important that your personal physician and/or the research nurse or study investigator be aware of all drugs you are taking, including those you buy without a prescription.
Last Reviewed: May 20, 2019